Abstract 4543
Background
IPI has shown durable overall survival (OS) in patients (pts) with MEL in clinical trials, but robust RW evidence is lacking. We present long-term RW outcomes from the IMAGE study (NCT01511913) in which pts received IPI and non-IPI therapies.
Methods
IMAGE was a large, multinational, prospective, observational study that enrolled adult pts with MEL treated with IPI or non-IPI from June 2012 to March 2015 and included > 3 years of follow-up. Adjusted OS curves were based on multivariate Cox regression models by adjusting for covariate effects. Progression-free survival (PFS) was analyzed using Kaplan-Meier methods. Patients self-administered the EORTC QLQ-C30, a validated, cancer-specific, health-related quality of life (QoL) questionnaire.
Results
Of 1356 pts, 1094 (81%) received IPI and 262 (19%) received non-IPI as index therapy. In all pts, median age was 64 years, 60% were male, 78% were from the EU, median time on study was 6 months, and 78% were pretreated (received ≥ 2 lines of therapy). In the IPI cohort, 780 pts (71%) remained on IPI and 314 (29%) switched to non-IPI. In the non-IPI cohort, 205 pts (78%) remained on non-IPI and 57 (22%) switched to IPI. Among 1151 pts who received IPI, 26% reported grade ≥ 3 treatment-related adverse events (AEs); most AEs occurred during year 1. The 3-year OS rates were 28% in the IPI and 25% in the non-IPI cohorts. In pretreated pts, OS rates were 25% in the IPI and 23% in the non-IPI cohorts. However, in treatment-naive pts, the OS rate in the IPI cohort was 40% compared with 33% in the non-IPI cohort, although the small sample size limits interpretation. Median PFS was 3 months in both the IPI and non-IPI cohorts. Completion rates for EORTC QLQ-C30 Global Health Status (GHS) score were 58%–80%. No major differences were observed in changes from baseline for EORTC QLQ-C30 GHS scores between the IPI and non-IPI cohorts, with similar trends of initial worsening and subsequent improvement.
Conclusions
Long-term, RW outcomes from IMAGE were consistent with those from IPI clinical trials. OS analysis across treatment-naive and pretreated pts suggested a beneficial role of IPI early in the disease with no detrimental impact on QoL.
Clinical trial identification
NCT01511913.
Editorial acknowledgement
Kakoli Parai, PhD, and Andrea Lockett at StemScientific, an Ashfield Company, funded by Bristol-Myers Squibb.
Legal entity responsible for the study
Bristol-Myers Squibb.
Funding
Bristol-Myers Squibb.
Disclosure
S. Dalle: Advisory / Consultancy, Research grant / Funding (self): Bristol-Myers Squibb; Research grant / Funding (self): Merck, Sharp & Dohme. L. Mortier: Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Bristol-Myers Squibb; Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: GlaxoSmithKline; Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Novartis; Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: LEO Pharma; Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Merck, Sharp & Dohme. P. Corrie: Honoraria (self), Advisory / Consultancy: Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Merck, Sharp & Dohme; Honoraria (self), Advisory / Consultancy: Pierre Fabre; Advisory / Consultancy: Incyte. R. Board: Honoraria (self), Advisory / Consultancy: Merck, Sharp & Dohme; Honoraria (self), Advisory / Consultancy: Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy: Pierre Fabre. A.M. Arance: Travel / Accommodation / Expenses: Bristol-Myers Squibb; Travel / Accommodation / Expenses: Merck, Sharp & Dohme; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Novartis; Travel / Accommodation / Expenses: Merck. F. Meiss: Honoraria (self), Non-remunerated activity/ies: Bristol-Myers Squibb. P. Terheyden: Research grant / Funding (self): Bristol-Myers Squibb. R. Gutzmer: Research grant / Funding (institution): Bristol-Myers Squibb. J. Brokaw: Full / Part-time employment: Bristol-Myers Squibb. T.K. Le: Full / Part-time employment: Bristol-Myers Squibb. J. Scotto: Shareholder / Stockholder / Stock options, Full / Part-time employment: Bristol-Myers Squibb. J. Lord-Bessen: Full / Part-time employment: Bristol-Myers Squibb. A. Moshyk: Shareholder / Stockholder / Stock options, Full / Part-time employment: Bristol-Myers Squibb. S. Kotapati: Shareholder / Stockholder / Stock options, Full / Part-time employment: Bristol-Myers Squibb. M.R. Middleton: Advisory / Consultancy: Amgen, GlaxoSmithKline, Novartis, Roche; Research grant / Funding (institution): AstraZeneca, GlaxoSmithKline, Novartis, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
5763 - cfDNA is an acceptable but insufficient means of characterizing FGFR3 mutation in patients with metastatic urothelial cancer (mUC)
Presenter: Sumanta Pal
Session: Poster Display session 3
Resources:
Abstract
5877 - Efficacy of anti-PD(L)1 treatment in patients with metastatic urothelial cancer based on mRNA- and protein- based PD-L1 determination: Results from the multicentric, retrospective FOsMIC trial
Presenter: Jonas Jarczyk
Session: Poster Display session 3
Resources:
Abstract
5204 - A differential bladder microbiota composition is associated with tumor grade in bladder cancer.
Presenter: Monica Parra-Grande
Session: Poster Display session 3
Resources:
Abstract
4904 - Molecular characterization of metastatic urothelial carcinoma (mUC) in prior or current smokers (PCS) vs non-smokers (NS)
Presenter: Victor Sacristan Santos
Session: Poster Display session 3
Resources:
Abstract
5370 - Evaluation of different diagnostic methods for identification of FGFR alteration in advanced urothelial carcinomas: Proficiency Results based on multiple RNA extraction kits and mutation detection methods
Presenter: Veronika Weyerer
Session: Poster Display session 3
Resources:
Abstract
2579 - Title: Genomic characterization of non-schistosomiasis-related squamous cell carcinoma (NSR-SCC) of the urinary bladder: a retrospective study of potential prognostic and predictive biomarkers
Presenter: Esmail Al-ezzi
Session: Poster Display session 3
Resources:
Abstract
2203 - TiNivo: Tivozanib combined with nivolumab results in prolonged progression free survival in patients with metastatic renal cell carcinoma (mRCC). Final Results.
Presenter: Philippe Barthelemy
Session: Poster Display session 3
Resources:
Abstract
4712 - First-Line Pembrolizumab (pembro) Monotherapy for Advanced Non‒Clear Cell Renal Cell Carcinoma (nccRCC): Updated Follow-Up for KEYNOTE-427 Cohort B
Presenter: Cristina Suárez
Session: Poster Display session 3
Resources:
Abstract
2091 - First-Line Pembrolizumab (pembro) Monotherapy in Advanced Clear Cell Renal Cell Carcinoma (ccRCC): Updated Follow-Up For KEYNOTE-427 Cohort A
Presenter: James Larkin
Session: Poster Display session 3
Resources:
Abstract
2368 - Association Between Depth of Response and Overall Survival: Exploratory Analysis in Patients With Previously Untreated Advanced Renal Cell Carcinoma (aRCC) in CheckMate 214
Presenter: Viktor Grünwald
Session: Poster Display session 3
Resources:
Abstract